Zero Point Five Therapeutics

Executive Summary

Zero Point Five Therapeutics (ZP5) is a private biotech based in Cambridge, MA, founded in 2020 to develop small molecule inhibitors targeting protein-protein interactions (PPIs) for oncology and neglected diseases. The company's PPI platform addresses previously undruggable targets, leveraging structure-based drug design to achieve high specificity. While still in early preclinical stages, ZP5's focus on both cancer and global health aligns with emerging trends in targeted therapy and access-to-medicine initiatives. The company has not disclosed a lead program or funding details, suggesting it remains in stealth or seed-stage development. Given the lack of public pipeline data, ZP5's near-term outlook is uncertain; however, its unique platform could attract partnership interest if initial validation emerges.

Upcoming Catalysts (preview)

• Q4 2026Lead Program Nomination and Preclinical Data Release30% success
• Q1 2027Series A Financing or Grant Award40% success
• 2027Collaboration/Partnership with Larger Pharma25% success